GLP-1 receptor agonist: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name) |
MDElliottMD (talk | contribs) Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved. |
||
| Line 1: | Line 1: | ||
'''GLP-1 receptor agonists''' (GLP-1 RAs, also called ''incretin mimetics'') are a class of injectable and (in one case) oral peptide medicines that bind and activate the [[GLP-1 receptor]].<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref> They were originally developed for [[type 2 diabetes mellitus]] and have since become first-line for [[obesity]],<ref name="step1">Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). ''NEJM'' 384:989. doi:10.1056/NEJMoa2032183</ref><ref name="surmount1">Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). ''NEJM'' 387:205. doi:10.1056/NEJMoa2206038</ref> approved for [[cardiovascular risk reduction]] in obesity without diabetes,<ref name="select">Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). ''NEJM'' 389:2221–32. doi:10.1056/NEJMoa2307563</ref> [[chronic kidney disease]] in T2DM,<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref> and [[MASH]] with stage 2–3 fibrosis.<ref name="essence">Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. {{Citation needed}}</ref> | '''GLP-1 receptor agonists''' (GLP-1 RAs, also called ''incretin mimetics'') are a class of injectable and (in one case) oral peptide medicines that bind and activate the [[GLP-1 receptor]].<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351. doi:10.1016/j.molmet.2021.101351</ref> They were originally developed for [[type 2 diabetes mellitus]] and have since become first-line for [[obesity]],<ref name="step1">Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). ''NEJM'' 384:989. doi:10.1056/NEJMoa2032183</ref><ref name="surmount1">Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). ''NEJM'' 387:205. doi:10.1056/NEJMoa2206038</ref> approved for [[cardiovascular risk reduction]] in obesity without diabetes,<ref name="select">Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). ''NEJM'' 389:2221–32. doi:10.1056/NEJMoa2307563</ref> [[chronic kidney disease]] in T2DM,<ref name="flow">Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). ''NEJM'' 391:109. doi:10.1056/NEJMoa2403347</ref> and [[MASH]] with stage 2–3 fibrosis.<ref name="essence">Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. {{Citation needed}}</ref> | ||
As of 2023, GLP-1 RAs were the largest growth driver in US outpatient medicine spending | As of 2023, GLP-1 RAs were the largest growth driver in US outpatient medicine spending, Ozempic alone accounted for $9.2 billion in Medicare Part D, second only to [[Eliquis]] across all federal programs.<ref name="cms2023">Centers for Medicare & Medicaid Services. ''Medicare Part D Drug Spending Dashboard, 2023.'' Gross spending, not net of manufacturer rebates. Available at: https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug</ref> | ||
== Mechanism == | == Mechanism == | ||
| Line 7: | Line 7: | ||
The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic β-cells, hypothalamic satiety neurons, gastric smooth muscle, cardiomyocytes, vascular endothelium, and renal tubules.<ref name="drucker2022"/><ref name="holst2022">Holst JJ (2022). GLP-1 incretin and pleiotropic hormone with pharmacological promise. ''Curr Opin Pharmacol'' 63:102189.</ref> Activation produces: | The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic β-cells, hypothalamic satiety neurons, gastric smooth muscle, cardiomyocytes, vascular endothelium, and renal tubules.<ref name="drucker2022"/><ref name="holst2022">Holst JJ (2022). GLP-1 incretin and pleiotropic hormone with pharmacological promise. ''Curr Opin Pharmacol'' 63:102189.</ref> Activation produces: | ||
* '''β-cell''': glucose-dependent insulin secretion | * '''β-cell''': glucose-dependent insulin secretion, meaning hypoglycemia risk is low compared to [[sulfonylureas]] or [[insulin]]<ref name="drucker2022"/> | ||
* '''α-cell''': glucagon suppression<ref name="drucker2022"/> | * '''α-cell''': glucagon suppression<ref name="drucker2022"/> | ||
* '''Stomach''': delayed gastric emptying → improved postprandial glucose and prolonged satiety<ref name="drucker2022"/> | * '''Stomach''': delayed gastric emptying → improved postprandial glucose and prolonged satiety<ref name="drucker2022"/> | ||
* '''CNS''': hypothalamic appetite suppression and modulation of reward circuitry | * '''CNS''': hypothalamic appetite suppression and modulation of reward circuitry, the mechanism behind both the weight loss and the widely-reported "food noise" quieting{{Citation needed}} | ||
* '''Cardiovascular and renal''': independent of glycemia | * '''Cardiovascular and renal''': independent of glycemia, endothelial improvement, natriuresis, weight-mediated and weight-independent blood pressure reduction, plaque stabilization<ref name="sattar2021">Sattar N et al. (2021). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis. ''Lancet Diabetes Endocrinol'' 9(10):653–62. doi:10.1016/S2213-8587(21)00203-5</ref> | ||
Native GLP-1 is rapidly cleaved by [[DPP-4]] and has a plasma half-life of approximately 2 minutes.<ref name="holst2022"/> Every clinically useful GLP-1 RA is engineered for DPP-4 resistance, either by amino-acid substitution at position 2 ([[liraglutide]], [[semaglutide]]),<ref name="drucker2022"/> structural fusion ([[dulaglutide]]'s Fc domain),<ref name="dulaglutide-label">US FDA. ''Trulicity (dulaglutide) prescribing information.'' Eli Lilly and Company. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s044lbl.pdf</ref> or by being a non-mammalian peptide ([[exenatide]], from Gila monster venom).<ref name="eng1992">Eng J et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from ''Heloderma suspectum'' venom. ''J Biol Chem'' 267(11):7402–5.</ref> | Native GLP-1 is rapidly cleaved by [[DPP-4]] and has a plasma half-life of approximately 2 minutes.<ref name="holst2022"/> Every clinically useful GLP-1 RA is engineered for DPP-4 resistance, either by amino-acid substitution at position 2 ([[liraglutide]], [[semaglutide]]),<ref name="drucker2022"/> structural fusion ([[dulaglutide]]'s Fc domain),<ref name="dulaglutide-label">US FDA. ''Trulicity (dulaglutide) prescribing information.'' Eli Lilly and Company. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125469s044lbl.pdf</ref> or by being a non-mammalian peptide ([[exenatide]], from Gila monster venom).<ref name="eng1992">Eng J et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from ''Heloderma suspectum'' venom. ''J Biol Chem'' 267(11):7402–5.</ref> | ||
| Line 37: | Line 37: | ||
== Problems == | == Problems == | ||
* '''Type 2 diabetes mellitus''' | * '''Type 2 diabetes mellitus''', first- or second-line per [[ADA Standards of Care|ADA 2025 Standards of Care]],<ref name="ada2025">American Diabetes Association. ''Standards of Care in Diabetes, 2025.'' ''Diabetes Care'' 48(Suppl. 1):S1–S352. doi:10.2337/dc25-S001</ref> especially when [[ASCVD]], [[heart failure]], [[CKD]], or obesity is co-present | ||
* '''Obesity or overweight with weight-related comorbidity''' | * '''Obesity or overweight with weight-related comorbidity''', BMI ≥30, or ≥27 with a weight-related condition (semaglutide 2.4 mg,<ref name="wegovy-label">US FDA. ''Wegovy (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</ref> tirzepatide,<ref name="zepbound-label">US FDA. ''Zepbound (tirzepatide) prescribing information.'' Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf</ref> liraglutide 3 mg<ref name="saxenda-label">US FDA. ''Saxenda (liraglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf</ref>) | ||
* '''Cardiovascular risk reduction in obesity without T2DM''' | * '''Cardiovascular risk reduction in obesity without T2DM''', semaglutide 2.4 mg (SELECT)<ref name="select"/> | ||
* '''MASH with stage 2–3 fibrosis''' | * '''MASH with stage 2–3 fibrosis''', semaglutide (FDA 2025, based on ESSENCE)<ref name="essence"/> | ||
* '''CKD in T2DM''' | * '''CKD in T2DM''', semaglutide adjunctive label (FLOW)<ref name="flow"/> | ||
== Key trials == | == Key trials == | ||
| Line 52: | Line 52: | ||
| '''SUSTAIN-6''' (2016) || Semaglutide SC || T2DM + high CV risk || 26% ↓ MACE<ref name="sustain6">Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). ''NEJM'' 375:1834–44. doi:10.1056/NEJMoa1607141</ref> | | '''SUSTAIN-6''' (2016) || Semaglutide SC || T2DM + high CV risk || 26% ↓ MACE<ref name="sustain6">Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). ''NEJM'' 375:1834–44. doi:10.1056/NEJMoa1607141</ref> | ||
|- | |- | ||
| '''REWIND''' (2019) || Dulaglutide || T2DM + CV risk or established CVD || 12% ↓ MACE | | '''REWIND''' (2019) || Dulaglutide || T2DM + CV risk or established CVD || 12% ↓ MACE, first GLP-1 RA benefit shown in ''primary'' prevention<ref name="rewind">Gerstein HC et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). ''Lancet'' 394(10193):121–30. doi:10.1016/S0140-6736(19)31149-3</ref> | ||
|- | |- | ||
| '''PIONEER-6''' (2019) || Semaglutide PO || T2DM + high CV risk || Non-inferior to placebo<ref name="pioneer6">Husain M et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER-6). ''NEJM'' 381:841–51. doi:10.1056/NEJMoa1901118</ref> | | '''PIONEER-6''' (2019) || Semaglutide PO || T2DM + high CV risk || Non-inferior to placebo<ref name="pioneer6">Husain M et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER-6). ''NEJM'' 381:841–51. doi:10.1056/NEJMoa1901118</ref> | ||
| Line 62: | Line 62: | ||
| '''SURMOUNT-1''' (2022) || Tirzepatide || Obesity without T2DM || Up to ~22.5% body-weight loss at 72 wk<ref name="surmount1"/> | | '''SURMOUNT-1''' (2022) || Tirzepatide || Obesity without T2DM || Up to ~22.5% body-weight loss at 72 wk<ref name="surmount1"/> | ||
|- | |- | ||
| '''SELECT''' (2023) || Semaglutide 2.4 mg || Obesity + established CVD, no T2DM || 20% ↓ MACE | | '''SELECT''' (2023) || Semaglutide 2.4 mg || Obesity + established CVD, no T2DM || 20% ↓ MACE, landmark for obesity as a CV target<ref name="select"/> | ||
|- | |- | ||
| '''STEP-HFpEF''' (2023) || Semaglutide || HFpEF + obesity || ↑ functional capacity (KCCQ), ↓ weight<ref name="stephfpef">Kosiborod MN et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). ''NEJM'' 389:1069–84. doi:10.1056/NEJMoa2306963</ref> | | '''STEP-HFpEF''' (2023) || Semaglutide || HFpEF + obesity || ↑ functional capacity (KCCQ), ↓ weight<ref name="stephfpef">Kosiborod MN et al. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). ''NEJM'' 389:1069–84. doi:10.1056/NEJMoa2306963</ref> | ||
| Line 79: | Line 79: | ||
'''Serious / labeled''': | '''Serious / labeled''': | ||
* '''Pancreatitis''' | * '''Pancreatitis''', labeled warning.<ref name="ozempic-label"/> Real-world data are mixed; recent large cohorts do not show a clear increase, and some show ''decreased'' acute pancreatitis incidence.<ref name="sattar2021"/> | ||
* '''Gallbladder disease''' | * '''Gallbladder disease''', cholelithiasis is partly driven by rapid weight loss.<ref name="wegovy-label"/> | ||
* '''Medullary thyroid carcinoma (MTC) / C-cell hyperplasia''' | * '''Medullary thyroid carcinoma (MTC) / C-cell hyperplasia''', boxed warning,<ref name="ozempic-label"/> based on rodent data. Humans show no calcitonin signal. Long-term follow-up >10 years has not been associated with increased thyroid cancer.<ref name="pollack2025">Pollack R, Stokar J (2025). Long-term GLP-1 receptor agonist use is not associated with incident thyroid cancer. ''Diabetes Metab Res Rev'' 41(8):e70104.</ref> The Bezin 2023 French case-control study found a weak signal that remains heavily debated.<ref name="bezin2023">Bezin J et al. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. ''Diabetes Care'' 46(2):384–90. doi:10.2337/dc22-1148</ref> '''Contraindicated in personal or family history of MTC or [[MEN2]].'''<ref name="ozempic-label"/> | ||
* '''[[NAION]]''' (non-arteritic anterior ischemic optic neuropathy) | * '''[[NAION]]''' (non-arteritic anterior ischemic optic neuropathy), emerging signal. Small absolute risk increase.<ref name="hsu2025">Hathaway JT, Shah MP, Hathaway DB et al. (2024). Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. ''JAMA Ophthalmol'' 142(8):732–9. doi:10.1001/jamaophthalmol.2024.2296</ref> | ||
* '''Aspiration risk under anesthesia''' | * '''Aspiration risk under anesthesia''', delayed gastric emptying. [[American Society of Anesthesiologists|ASA]] 2024 guidance: hold weekly agents 7 days pre-op; daily agents skip the morning dose.<ref name="kindel2024">Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. ''Surg Obes Relat Dis'' 20(12):1183–8.</ref> | ||
* '''Suicidality''' | * '''Suicidality''', initial EMA signal not replicated. Subsequent large studies suggest ''reduced'' suicidal ideation.<ref name="wang2024">Wang W, Volkow ND, Berger NA et al. (2024). Association of semaglutide with risk of suicidal ideation in a real-world cohort. ''Nat Med'' 30:168–76. doi:10.1038/s41591-023-02672-2</ref> FDA removed suicidality warnings January 2026.{{Citation needed}} | ||
'''Other monitored''':<ref name="ozempic-label"/> | '''Other monitored''':<ref name="ozempic-label"/> | ||
| Line 99: | Line 99: | ||
The discovery story is one of the great late-20th-century pharmacological narratives. | The discovery story is one of the great late-20th-century pharmacological narratives. | ||
Native GLP-1 was isolated in the late 1980s by Jens Juul Holst (Copenhagen) and Daniel Drucker (Toronto).<ref name="holst2022"/> Its therapeutic potential was obvious | Native GLP-1 was isolated in the late 1980s by Jens Juul Holst (Copenhagen) and Daniel Drucker (Toronto).<ref name="holst2022"/> Its therapeutic potential was obvious, and so was its problem: a 2-minute plasma half-life.<ref name="holst2022"/> | ||
In 1992, John Eng, an endocrinologist at the Bronx VA Medical Center, was reading work by Pisano and Raufman noting that the venom of the [[Gila monster]] (''Heloderma suspectum'') caused [[pancreatitis]] in laboratory animals.{{Citation needed}} Eng hypothesized that the venom must contain something incretin-like | In 1992, John Eng, an endocrinologist at the Bronx VA Medical Center, was reading work by Pisano and Raufman noting that the venom of the [[Gila monster]] (''Heloderma suspectum'') caused [[pancreatitis]] in laboratory animals.{{Citation needed}} Eng hypothesized that the venom must contain something incretin-like, and isolated exendin-4, a 39-amino-acid peptide 53% homologous to human GLP-1, but naturally resistant to DPP-4 cleavage.<ref name="eng1992"/> The VA declined to patent the discovery, so Eng patented it personally in 1993, licensed it to Amylin Pharmaceuticals, and the rest of the class, Byetta in 2005, then Victoza, Trulicity, Ozempic, Mounjaro, flowed from that single venom isolation.{{Citation needed}} | ||
== Spending and access context == | == Spending and access context == | ||
| Line 112: | Line 112: | ||
* Mounjaro: $2.4 billion Part D (first full year) | * Mounjaro: $2.4 billion Part D (first full year) | ||
These are gross figures | These are gross figures, net spend after manufacturer rebates is materially lower, often 30–50% off list.<ref name="cms2023"/> | ||
== See also == | == See also == | ||